<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of thoracic central venous obstruction
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of thoracic central venous obstruction
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of thoracic central venous obstruction
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albeir Y Mousa, MD, FACS, MBA, MPH, RPVI
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vineet Chopra, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Eidt, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph L Mills, Sr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ingemar Davidson, MD, PhD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1027907003">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term thoracic central venous obstruction (TCVO) encompasses a spectrum of disease affecting the veins in the chest that varies considerably in etiology, manifestations, implications, and approach to therapy. TCVO is a significant medical condition that can affect the ability to provide necessary care due to loss of venous access sites and can also impair upper extremity functioning and quality of life. Treatment of TCVO is tailored to address symptoms when they occur and the underlying venous and other anatomic abnormalities.
        </p>
        <p>
         An overview of the etiologies, clinical presentations, and treatment of TCVO is reviewed. Specific etiologies are discussed in more detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">
          "Central vein obstruction associated with upper extremity hemodialysis access"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1757946175">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obstruction of venous flow
         <strong>
         </strong>
         can be described as central (nearer the heart) or peripheral (away from the heart). Central and peripheral venous obstruction can relate to the upper or lower extremity. Definitions surrounding iliocaval and/or lower extremity venous obstruction are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">
          "Overview of iliocaval venous obstruction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3299319319">
         <span class="h2">
          Thoracic central venous obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         TCVO refers to obstruction of systemic (ie, central) veins located in the chest (ie, thoracic) cavity. As described below, this includes the subclavian veins, the thoracic segment of the internal jugular veins, brachiocephalic veins, the superior vena cava, and the suprahepatic portion of the inferior vena cava  (
         <a class="graphic graphic_figure graphicRef134982" href="/z/d/graphic/134982.html" rel="external">
          figure 1
         </a>
         ). TCVO may be related to venous luminal narrowing that impedes blood flow (partially or completely) due to a variety of causes (eg, intimal hyperplasia, scarring, thrombus, external compression). Thrombosis of thoracic central veins (ie, thrombotic TCVO) is synonymous with deep vein thrombosis (DVT); moreover, thrombosis of the more peripheral upper extremity veins (eg, axillary, brachial) can also lead to TCVO.
        </p>
        <p class="headingAnchor" id="H1201746896">
         <span class="h2">
          Upper extremity venous obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         TCVO is distinguished from upper extremity venous obstruction, which refers to obstruction of the deep or superficial veins of the upper extremity. The deep veins of the upper extremity include the axillary veins, the single or paired brachial veins, and paired forearm veins (radial, ulnar, interosseous). The main superficial veins of the upper extremity include the cephalic (lateral), basilic (medial), cubital, and antecubital veins. Upper extremity venous obstruction may also be partial (ie, stenosis) or complete (ie, occlusion), but due to the smaller size of the involved veins and lower flow, stenosis of upper extremity veins often results in complete thrombosis.
        </p>
        <p>
         The most common etiology for upper extremity venous obstruction is due to indwelling central venous catheters or from pacemaker wire leads. In addition, advanced axillary lymphadenopathy can compress the axillary vein and present as a thrombotic axillary venous outflow condition associated with inflammatory breast cancer [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2865270">
         <span class="h2">
          Deep vein thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombosis of the thoracic central veins (ie, thrombotic TCVO) and/or deep veins of the upper extremity constitutes DVT. Thrombosis of the thoracic central veins is often contiguous with thrombosis of the deep vein of the upper extremity or may occur in addition to upper extremity deep venous thrombosis as part of a systemic response.
        </p>
        <p>
         Thrombosis of the deep veins of the upper extremity constitutes upper extremity DVT. As in the lower extremity, primary upper extremity DVT is present when there is no discernable cause, and secondary upper extremity DVT is present when an inciting cause (eg, intravenous catheter) is present. Thrombosis of the deep veins of the upper extremity veins is often caused by indwelling central venous catheters and is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/116371.html" rel="external">
          "Peripherally inserted central catheter (PICC)-related venous thrombosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H648102819">
         <span class="h1">
          CENTRAL VENOUS ANATOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Venous obstruction is defined as a luminal narrowing that impedes venous blood ﬂow. A full understanding of the thoracic vascular anatomy and the anatomy of the thoracic outlet helps guide our understanding of the etiology and also highlights available options for treatment, which may include surgery.
        </p>
        <p>
         The central venous system is divided into two components: the thoracic central venous system (TCVS) and the iliocaval (pelvic) central venous system. The components of the TCVS are reviewed. The iliocaval venous system is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/15223.html" rel="external">
          "Overview of iliocaval venous obstruction", section on 'Iliocaval anatomy'
         </a>
         .)
        </p>
        <p>
         In addition to the central (ie, systemic) veins, other veins within the chest include the somatic veins (eg, azygos/hemiazygos), superficial veins, chest wall veins, or visceral veins (eg, pulmonary veins, coronary sinus). Somatic veins relate to the trunk or body wall and are also known as parietal veins. In general, these provide drainage of structures with voluntary innervation whereas the visceral veins generally provide drainage to structures with autonomic, involuntary innervation.
        </p>
        <p class="headingAnchor" id="H2759086891">
         <span class="h2">
          Thoracic central veins
         </span>
         <span class="headingEndMark">
          —
         </span>
         A multidisciplinary committee has published reporting standards for central venous disease and presents what we feel should be adopted as a standard definition [
         <a href="#rid2">
          2
         </a>
         ]. The TCVS consists of those veins located inferior to the thoracic outlet "superior thoracic aperture," central to the inner margin of first rib, and superior to the diaphragmatic hiatus  (
         <a class="graphic graphic_figure graphicRef134982" href="/z/d/graphic/134982.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. The components of the system are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intrathoracic segments of internal jugular veins – The internal jugular (IJ) veins have a cervical and a central portion. The central portion begins at the superior margin of the first rib and passes through the thoracic outlet. It terminates posterior to the center of the sternal head of the clavicle by merging with the subclavian (SC) vein to form the brachiocephalic (BC) vein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subclavian veins – The SC veins are the central continuation of the axillary veins, beginning just medial to the confluence of the cephalic arch and axillary vein  (
         <a class="graphic graphic_figure graphicRef74801" href="/z/d/graphic/74801.html" rel="external">
          figure 2
         </a>
         ), where the SC vein crosses in a special groove over the superior surface of the first rib, merging with the central portion of the IJ veins to form the BC vein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brachiocephalic veins – The BC veins originate at the confluence of the IJ and SC veins. The left BC vein meets the right BC vein to the right of the midline and posterior to the manubrium to form the superior vena cava (SVC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superior vena cava – The SVC  (
         <a class="graphic graphic_figure graphicRef81142" href="/z/d/graphic/81142.html" rel="external">
          figure 3
         </a>
         ) originates at the confluence of the right and left BC veins and extends to the right atrium, terminating posterior to the right atrial appendage at the superior cavoatrial junction. This is approximately 2.5 vertebral body units (one vertebral body with one adjacent intravertebral disc) inferior to the carina [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suprahepatic portion of the inferior vena cava – The suprahepatic inferior vena cava (IVC) originates at the inferior cavoatrial junction and extends to the level of the diaphragm.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21982748">
         <span class="h2">
          Collateral venous circulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Collateral venous flow refers to the condition in which alternative paths for blood flow emerge when the main venous pathways are obstructed.
        </p>
        <p>
         When TCVO develops, drainage of venous blood will rely mainly on other veins including the azygos and hemiazygos veins; less commonly, venous return will depend on the superficial, paraspinal, epidural, and body wall veins. It is important to mention that the azygos vein ascends from the abdomen into the chest, turning anteriorly to drain directly into the posterior wall of the SVC, and it joins the SVC between the confluence of the BC veins superiorly and the right atrium  (
         <a class="graphic graphic_figure graphicRef81142" href="/z/d/graphic/81142.html" rel="external">
          figure 3
         </a>
         ). Therefore, occlusion of SVC at that location is considered the most severe type of TCVO, as it hinders all possible collateral venous drainage when central veins are occluded and in that condition reverses flow in the azygos vein into the lower venous system and the IVC  (
         <a class="graphic graphic_diagnosticimage graphicRef135248" href="/z/d/graphic/135248.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         In addition, shoulder collaterals become  (
         <a class="graphic graphic_picture graphicRef81445" href="/z/d/graphic/81445.html" rel="external">
          picture 1
         </a>
         ) very visible with advanced TCVO. It may involve the lateral thoracic vein, subscapular vein, suprascapular vein, and intercostal veins. In TCVO, shoulder collaterals can then bypass the blockage by direct drainage into the SC and axillary system or drain into the azygos system via the chest wall. It has been reported that the costoaxillary veins in advanced TCVO can connect the first to seventh intercostal veins to the lateral thoracic vein [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Uncommon collaterals include veins within the mediastinum and the pulmonary vasculature [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2844272063">
         <span class="h2">
          Thoracic outlet
         </span>
         <span class="headingEndMark">
          —
         </span>
         The thoracic outlet is the space between the clavicle (collarbone), the first rib, and multiple muscles/ligaments.
        </p>
        <p>
         As the subclavian-axillary vein crosses from the axilla to the chest, the venous structure passes through two important anatomic spaces, which can become narrowed, leading to venous compression [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The interscalene triangle  (
         <a class="graphic graphic_figure graphicRef59433" href="/z/d/graphic/59433.html" rel="external">
          figure 4
         </a>
         ) is the space between the first rib and scalene muscles (anterior and middle). Through this triangle, the SC artery and brachial plexus cross to the upper extremity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The costoclavicular space  (
         <a class="graphic graphic_figure graphicRef120517" href="/z/d/graphic/120517.html" rel="external">
          figure 5
         </a>
         ) is a location where the subclavian-axillary venous segment is vulnerable to external compression at the junction of the first rib, clavicle, the subclavius muscle, and the costoclavicular ligament (Halsted ligament) [
         <a href="#rid8">
          8
         </a>
         ]. This triangle is crucial in developing TCVO, and it may create the anatomic "nutcracker" effect of the first rib and clavicle [
         <a href="#rid9">
          9
         </a>
         ]. In addition, hypertrophied subclavius muscle or costoclavicular ligament may introduce additional pressure to the tight space of the costoclavicular junction [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A significant number of thoracic central vein stenotic lesions occur at the junction of the first rib and the clavicle (ie, costoclavicular junction, thoracic outlet). It is felt that some, if not many, of these are related at least in part to external compression [
         <a href="#rid13">
          13,14
         </a>
         ]. In one study, 48 cases were reviewed retrospectively, looking for extrinsic compression of the left BC vein [
         <a href="#rid15">
          15
         </a>
         ]. The presence of collaterals was noted as well as the presence of any intrinsic stenosis of the left BC or SC veins. Some degree of extrinsic compression was observed in 21 patients (44 percent). Twelve (25 percent) had mild compression, six (13 percent) had moderate compression, and three (6 percent) had severe compression. Collateral veins were seen in 11 of 21. All three patients with severe extrinsic compression were symptomatic and were treated with stent placement.
        </p>
        <p>
         An accessory muscular band that crosses the axilla may cause TCVO, and this unusual anatomic variant is referred to as Langer axillary arch, and in most cases dividing that aberrant muscular band is an essential element of treatment and is needed for full recovery [
         <a href="#rid10">
          10
         </a>
         ]. Hypertrophy of the anterior scalene muscle (which lies behind the SC vein), the subclavius muscle underlying the clavicle, and the costoclavicular ligament may all further reduce the costoclavicular space in the anterior portion of the thoracic outlet and cause TCVO.
        </p>
        <p class="headingAnchor" id="H767204062">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on clinical presentation, TCVO can be classified by the presence or absence of thrombus as either thrombotic or nonthrombotic, respectively. TCVO is also classified based on whether there is an inciting etiology (ie, secondary) or not (ie, primary).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TCVO is commonly classified as thrombotic or nonthrombotic based on the presence or absence of thrombus, respectively, within the vein. A subset of patients have symptoms but no thrombosis, which is termed intermittent obstruction (ie, McCleery syndrome) [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="local">
          'Intermittent partial nonthrombotic obstruction'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TCVO can also be classified as primary or secondary depending upon whether there is an inciting etiology. Secondary obstruction of the thoracic central veins is more common compared with primary (direct) causes and is usually associated with indwelling catheters or wires that occupy a significant proportion of the cross-sectional diameter of the vessel. Primary TCVO is classified as traumatic (iatrogenic, gunshot, stab) or as effort thrombosis (also known as Paget-Schroetter syndrome). (See
         <a class="medical medical_review" href="/z/d/html/15227.html" rel="external">
          "Overview of blunt and penetrating thoracic vascular injury in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TCVO can be due to due to endoluminal pathology or external compression from adjacent structures or pathology. (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obstruction may be partial (ie, stenotic lesion, nonocclusive thrombus) or complete (ie, occlusive lesion; chronic venous changes, occlusive thrombus) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TCVO can be classified anatomically based on the location of affected veins. Reporting standards published by a committee of the Society of Interventional Radiology present a comprehensive review of issues that should be determined in evaluating patients and for reporting data dealing with this condition  (
         <a class="graphic graphic_figure graphicRef117576" href="/z/d/graphic/117576.html" rel="external">
          figure 6
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. An important aspect of this document is the establishment of an anatomic classification for TCVO reflecting increasingly severe degrees of involvement.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3335788860">
         <span class="h1">
          ETIOLOGIES
         </span>
        </p>
        <p class="headingAnchor" id="H2876872459">
         <span class="h2">
          Intravascular device related
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravascular devices placed into the thoracic central venous system are the most common cause of TCVO, primarily related to indwelling catheters positioned in or traversing through the subclavian (SC) vein [
         <a href="#rid18">
          18-22
         </a>
         ]. Owing to the larger caliber of the catheter, TCVO is an ongoing clinical concern in patients dialyzed through an upper-extremity catheter in whom TCVO is reported to occur in up to 30 percent  (
         <a class="graphic graphic_diagnosticimage graphicRef120531" href="/z/d/graphic/120531.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef120523" href="/z/d/graphic/120523.html" rel="external">
          image 3
         </a>
         ) [
         <a href="#rid23">
          23
         </a>
         ]. Wires for pacemakers and defibrillators may have similar effects on the central venous system [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">
          "Central vein obstruction associated with upper extremity hemodialysis access"
         </a>
         .)
        </p>
        <p>
         It is intuitive that indwelling catheter-induced trauma after insertion into the central venous system can damage venous endothelium to initiate a chain of local and systemic inflammatory responses, which can result in stenosis, scarring, and/or obstruction of the central venous system. In addition, the turbulence of flow from the catheter may add intimal hyperplasia, which could augment the degree of stenosis/occlusion of the central venous system [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
         Autopsy studies have demonstrated that intimal injury associated with focal endothelial denudation occurs acutely due to mechanical irritation from an indwelling foreign object [
         <a href="#rid27">
          27
         </a>
         ]. In addition, the high-flow state induced by an indwelling catheter causes regions of increased turbulence that can also cause injury [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p>
         Chronic changes include focal attachments to the vein wall with thrombus, increased smooth muscle cells, vein wall thickening, and eventually collagen deposition. If a central venous catheter is observed with fluoroscopy, it can be seen to be in constant motion due to the movements of mediastinal structures created by the beating of the heart and the motions associated with respiration. Anatomic differences between right-sided and left-sided thoracic central veins and differing incidences of stenosis from side to side support the mechanical trauma theory [
         <a href="#rid31">
          31-34
         </a>
         ].
        </p>
        <p>
         Any intravenous catheter has the potential to cause venous thrombosis. These include tunneled and nontunneled central venous catheters, port devices, and peripherally inserted central catheters (PICCs) [
         <a href="#rid35">
          35-38
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nontunneled catheters – The propensity for nontunneled catheters to cause TCVO, as well as the marked increase in the incidence of catheter-related infection, limits the duration of their use. In addition, some nontunneled catheters (eg, hemodialysis) are relatively stiff, resulting in increased mechanical trauma to the vein during insertion. (See
         <a class="medical medical_review" href="/z/d/html/131350.html" rel="external">
          "Central venous access: acute and emergency access in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tunneled catheters – The frequency with which prior central catheter use caused TCVO in hemodialysis patients varies according to the vein used for catheter introduction, the type of catheter that is used, the duration of catheter use (ie, catheter contact time), and the number of catheters that have been placed. (See
         <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">
          "Central vein obstruction associated with upper extremity hemodialysis access"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripherally inserted central catheters – The incidence of TCVO for PICCs is between 5 and 15 percent for hospitalized patients and 2 to 5 percent for ambulatory patients [
         <a href="#rid39">
          39
         </a>
         ]. In a study in which venography was performed before and after insertion of PICCs in 150 patients, 7.5 percent of patients with previously normal central veins developed angiographic abnormalities after PICC placement (central venous stenosis in 4.8 percent, central venous occlusion in 2.7 percent) [
         <a href="#rid40">
          40-45
         </a>
         ]. Of note, many of these thrombotic events may be clinically asymptomatic. (See
         <a class="medical medical_review" href="/z/d/html/116371.html" rel="external">
          "Peripherally inserted central catheter (PICC)-related venous thrombosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac implantable electronic devices (CIEDs) have also been associated with TCVO. The pathogenesis for the development of stenosis in association with the transvenous leads of a CIED is thought to be mechanical irritation. These leads are generally introduced through the SC vein, which is the most frequently involved vessel. However, the brachiocephalic (BC) vein and superior vena cava (SVC) can also be involved. In some patients, SVC syndrome has developed in association with both a catheter and transvenous CIED leads passing through the SVC. (See
         <a class="medical medical_review" href="/z/d/html/131420.html" rel="external">
          "Clinical features, diagnosis, and classification of thoracic central venous obstruction", section on 'Edema and pain'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         A variety of catheter-related factors influence the incidence and severity of TCVO. These are reviewed briefly and discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Catheter-related factors'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Catheter diameter – The diameter of the catheter relative to the size of the vein (so-called "catheter-to-vein ratio") determines whether blood flows freely around the catheter or stagnates [
         <a href="#rid46">
          46-48
         </a>
         ]. For a vein of similar size, thrombosis is more likely with a larger diameter catheter (eg, plasmapheresis, hemodialysis, multilumen catheters) compared with a smaller catheter (eg, single lumen or smaller gauge).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insertion site and lesion location – Although SC and internal jugular (IJ) cannulation sites are more commonly blamed for TCVO, peripheral insertion sites for central venous catheters are also associated with an increased incidence of venous stenosis [
         <a href="#rid40">
          40,49-51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For IJ catheters, a left-sided catheter may be more commonly involved [
         <a href="#rid31">
          31-34
         </a>
         ]. A left-sided catheter must be longer due to the greater distance required to traverse the chest, and the catheter must traverse several anatomic angulations [
         <a href="#rid52">
          52
         </a>
         ]. These are located between the left IJ and left BC vein, an angle created as the BC vein crosses over the BC artery and aorta where the vein is subjected to pulsations and potentially extrinsic compression [
         <a href="#rid15">
          15
         </a>
         ], and lastly between the left BC vein and SVC [
         <a href="#rid53">
          53
         </a>
         ]. The left IJ vein also has a smaller cross-sectional area compared with the right IJ vein [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For SC catheters, the sharp curve at the junction of the SC and BC veins along with the movement of these structures with the beating of the heart and respiratory movement is thought to result in endothelial injury both during insertion and the life of the catheter, possibly leading to neointimal hyperplasia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Catheter malposition – Malposition of the tip of a central catheter may be associated with an increased risk of TCVO. (See
         <a class="medical medical_review" href="/z/d/html/1906.html" rel="external">
          "Malfunction of chronic hemodialysis catheters"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116371.html" rel="external">
          "Peripherally inserted central catheter (PICC)-related venous thrombosis in adults", section on 'Device factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Catheter-related infection – A relationship between TCVO and catheter-related infection has also been reported. However, it should be noted that accurate evaluation of the relationship between catheter-associated infection and TCVO is difficult because of multiple confounding variables [
         <a href="#rid55">
          55-57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122940.html" rel="external">
          "Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1966.html" rel="external">
          "Tunneled hemodialysis catheter-related bloodstream infection (CRBSI): Management and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritant or vesicant phlebitis – Thrombosis can occur as a reaction to the catheter material or to the infused drugs contacting the venous intima. Common culprits include
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         ,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         , certain antibiotics (eg,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         ), chemotherapy agents, and hypotonic (&lt;250 mOsm/kg) or hypertonic (&gt;350 mOsm/kg) electrolyte solutions [
         <a href="#rid58">
          58
         </a>
         ]. Some such agents also have irritant or vesicant properties and can cause necrosis of the subcutaneous tissues if leakage outside the vein occurs  (
         <a class="graphic graphic_table graphicRef127371" href="/z/d/graphic/127371.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef67517" href="/z/d/graphic/67517.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef67155" href="/z/d/graphic/67155.html" rel="external">
          table 3
         </a>
         ). It is important to note that not all vesicant agents cause venous irritation during the injection. For this reason, verification of the central location (ie, cavoatrial junction) of the catheter tip is essential when infusing these agents. (See
         <a class="medical medical_review" href="/z/d/html/115957.html" rel="external">
          "Central venous access: Device and site selection in adults", section on 'Nature of infusate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2797.html" rel="external">
          "Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hormonal factors – An association between hormonal influences and primary (ie, non-catheter-related) TCVO has been established. Observational studies suggest that patients who receive PICCs during pregnancy for a variety of indications experience a high rate of thrombosis [
         <a href="#rid59">
          59,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1349.html" rel="external">
          "Deep vein thrombosis in pregnancy: Epidemiology, pathogenesis, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral contraceptives may increase the risk for catheter-related TCVO when used in a patient with prothrombotic mutations, such as prothrombin 20210 or factor V Leiden [
         <a href="#rid61">
          61,62
         </a>
         ]. Case reports of catheter-related TCVO (with or without coagulation abnormalities) are also reported to occur with ovulation induction and in vitro fertilization [
         <a href="#rid63">
          63-65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2913334967">
         <span class="h2">
          Postthrombotic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior deep vein thrombosis (DVT) also increases the risk for subsequent venous thrombosis, particularly in the setting of central venous catheter placement [
         <a href="#rid46">
          46,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8200.html" rel="external">
          "Post-thrombotic (postphlebitic) syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3016946142">
         <span class="h2">
          Malignant obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Malignancies that more typically lead to right-sided thoracic venous obstruction and SVC syndrome include lung cancer and non-Hodgkin lymphoma, which are responsible for approximately 95 percent of the cases of malignancy-related SVC syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome", section on 'Typical malignancies'
         </a>
         .)
        </p>
        <p>
         Advanced axillary lymphadenopathy and compression on axillary vein can also obstruct axillary venous outflow (eg, inflammatory breast cancer).
        </p>
        <p class="headingAnchor" id="H4103276339">
         <span class="h2">
          Aneurysmal disease or aortic ectasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         One of the more frequent causes of external venous compression occurs when there is ectasia of the aortic arch or its branches [
         <a href="#rid67">
          67
         </a>
         ]. When this occurs, a deformity of the left BC vein may be seen on imaging. Support suggesting that this deformity is causing a true obstruction can be confirmed by the presence of collateral veins peripheral to the deformity. It is important that this situation is recognized for what it is; attempts to dilate the vein with an angioplasty balloon will have no effect. Some have suggested stenting in cases with significant symptoms; however, placement may be difficult owing to the large size of the vein [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16209.html" rel="external">
          "Overview of aneurysmal disease of the aortic arch branches or upper extremity arteries in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1298032255">
         <span class="h2">
          Iatrogenic or traumatic vessel injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thoracic venous injuries are predominantly due to traumatic and iatrogenic causes [
         <a href="#rid68">
          68
         </a>
         ]. The narrow space of the costoclavicular region in combination with repeated trauma can lead to intrinsic damage to the tunica intima, flow turbulence, and intimal hyperplasia, which in turn could result in the activation of the coagulation cascade and initiate the thrombus formation. Long-standing external trauma to the subclavian/axillary vein will also result in scarring and fibrosis of the vein  (
         <a class="graphic graphic_diagnosticimage graphicRef131681" href="/z/d/graphic/131681.html" rel="external">
          image 4
         </a>
         ). Clavicular fracture has also been reported as a cause of subclavian-axillary venous thrombosis [
         <a href="#rid68">
          68,69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15227.html" rel="external">
          "Overview of blunt and penetrating thoracic vascular injury in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H401958172">
         <span class="h2">
          Venous thoracic outlet syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thoracic outlet syndrome (TOS) is an anatomic disorder first described in 1956 as bony  (
         <a class="graphic graphic_diagnosticimage graphicRef120527" href="/z/d/graphic/120527.html" rel="external">
          image 5
         </a>
         and
         <a class="graphic graphic_figure graphicRef50430" href="/z/d/graphic/50430.html" rel="external">
          figure 7
         </a>
         ), muscular, or ligamentous compression of the brachial plexus, arteries, and veins as they cross through the thoracic outlet space  (
         <a class="graphic graphic_diagnosticimage graphicRef120519" href="/z/d/graphic/120519.html" rel="external">
          image 6
         </a>
         ) between the clavicle and upper ribs [
         <a href="#rid70">
          70
         </a>
         ]. Compression by subclavius and anterior scalene muscles has also been reported (ie, McCleery syndrome) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         The manifestations of TOS is usually related to compression of any of these three structures  (
         <a class="graphic graphic_figure graphicRef120517" href="/z/d/graphic/120517.html" rel="external">
          figure 5
         </a>
         ); however, a combination of structures and symptoms may also occur  (
         <a class="graphic graphic_figure graphicRef120517" href="/z/d/graphic/120517.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid19">
          19,72,73
         </a>
         ]. Among the three main types of TOS (neurogenic, arterial, venous [vTOS]), vTOS comprises 5 percent of cases  (
         <a class="graphic graphic_diagnosticimage graphicRef120525" href="/z/d/graphic/120525.html" rel="external">
          image 7
         </a>
         ) [
         <a href="#rid74">
          74
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15208.html" rel="external">
          "Overview of thoracic outlet syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis"
         </a>
         .)
        </p>
        <p>
         The presentation of vTOS can be thrombotic (more common) or nonthrombotic. The most common clinical presentation of thrombotic vTOS is acute thrombosis of subclavian-axillary vein segment (ie, Paget-Schroetter syndrome)  (
         <a class="graphic graphic_diagnosticimage graphicRef132018" href="/z/d/graphic/132018.html" rel="external">
          image 8
         </a>
         ), which typically affects young, high-performance, athletic individuals, or people who elevate their arms above the head for extended periods of time [
         <a href="#rid75">
          75-77
         </a>
         ]. Acute thrombotic events are usually associated with arm swelling, bluish discoloration, numbness, and pain. In cases of advanced chronic occlusion, they are usually associated with extensive collateral pathways over neck, chest wall, and arms. Venous TOS is more common on the right, which in most cases reflects the dominant extremity [
         <a href="#rid78">
          78,79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Epidemiology and risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Clinical presentations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H521980650">
         <span class="h2">
          Hypercoagulability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital or acquired systemic prothrombotic conditions may increase the risk of TCVO [
         <a href="#rid80">
          80-87
         </a>
         ]. Studies have also assessed the interaction between an underlying hypercoagulable state and the local injury caused by the indwelling central venous catheters [
         <a href="#rid61">
          61,88
         </a>
         ].
        </p>
        <p>
         A higher incidence (up to 32 percent) of symptomatic catheter-related upper extremity DVT is found in patients with underlying malignancies [
         <a href="#rid89">
          89-91
         </a>
         ]. Patients with malignancy involving the right lung, lymph nodes, or other mediastinal structures can present with thrombosis due to central vein compression. (See
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2243667832">
         <span class="h1">
          CLINICAL PRESENTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of TCVO depends upon the acuity (acute, chronic), severity of obstruction (partial, complete), the location of the obstruction, and the extent of any venous compensation (ie, collateral flow).
        </p>
        <p class="headingAnchor" id="H4067506977">
         <span class="h2">
          Acute thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute thrombotic obstruction of the central veins can occur in the setting of a previously widely patent vessel (eg, previous history of venous thoracic outlet syndrome) or in a vein with a preexisting stenosis (stenotic veins from previous instrumentation or continuous chronic friction at the thoracic outlet). The patient is often aware when symptoms started and can generally relate their occurrence to any antecedent events.
        </p>
        <p>
         Acute symptoms and signs of TCVO can include pain, swelling (upper extremity, neck, face), chest pain, respiratory symptoms (ie, related to pulmonary embolism), or neurologic manifestations (ie, related to paradoxical embolism, cerebral edema). (See
         <a class="medical medical_review" href="/z/d/html/131420.html" rel="external">
          "Clinical features, diagnosis, and classification of thoracic central venous obstruction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1436322685">
         <span class="h2">
          Intermittent partial nonthrombotic obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of cases of partial nonthrombotic obstruction present with intermittent symptoms (also called McCleery syndrome [
         <a href="#rid17">
          17
         </a>
         ]).
        </p>
        <p>
         Intermittent, nonthrombotic obstruction is associated with dull aching pain, engorged upper extremity superficial veins, and dependent swelling. In addition, most of these patients developed significant venous collaterals that help with the drainage of the arm  (
         <a class="graphic graphic_picture graphicRef76917" href="/z/d/graphic/76917.html" rel="external">
          picture 2
         </a>
         ). Besides the swelling, hand cyanosis and pain (venous claudication) and paresthesias may be present as well [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
         One study highlighted the occurrence of intermittent ipsilateral arm swelling as an integral diagnostic component for those who presented with nonthrombotic TCVO [
         <a href="#rid92">
          92
         </a>
         ]. Symptoms of intermittent obstruction mandate a targeted workup to rule out TCVO [
         <a href="#rid93">
          93
         </a>
         ]. Subclavian-axillary vein compression can be provoked by upper arm abduction and demonstrated on venography  (
         <a class="graphic graphic_diagnosticimage graphicRef120519" href="/z/d/graphic/120519.html" rel="external">
          image 6
         </a>
         ) [
         <a href="#rid94">
          94
         </a>
         ]. However, the Adson test (rotating head toward the ipsilateral extremity and feeling for loss of radial pulse during arm abduction) is not reliable, as it can be positive in up to 50 percent of the general population [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2205130053">
         <span class="h2">
          Chronic progressive occlusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         With complete venous occlusion, there is a triad of pain, cyanosis, and swelling [
         <a href="#rid96">
          96,97
         </a>
         ]. Hand paresthesias associated with the swelling has been also reported secondary to anoxic nerve injury or from nerve compression from surrounding soft tissue edema [
         <a href="#rid98">
          98
         </a>
         ]. Upper extremity swelling worsens with exercise or arm dependency [
         <a href="#rid97">
          97
         </a>
         ]. The sequela normally starts with repetitive trauma to the subclavian vein and continues with compression at the costoclavicular region. In turn, this leads to the development of a sclerosed vein with damaged tunica intima along with intraluminal sclerotic web, which usually leads to venous outflow obstruction with subsequent propagation of a blood clot to the axillary vein. Significant superficial collateral venous engorgement is usually seen  (
         <a class="graphic graphic_diagnosticimage graphicRef120522" href="/z/d/graphic/120522.html" rel="external">
          image 9
         </a>
         ) [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H78100738">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of TCVO may be suspected based upon history and physical exam but requires demonstration of venous stenosis or obstruction affecting the thoracic central veins on venous imaging studies  (
         <a class="graphic graphic_algorithm graphicRef139014" href="/z/d/graphic/139014.html" rel="external">
          algorithm 1
         </a>
         ). Duplex ultrasound is often the initial imaging modality for most patients with suspected TCVO to identify obstruction  (
         <a class="graphic graphic_diagnosticimage graphicRef120526" href="/z/d/graphic/120526.html" rel="external">
          image 10
         </a>
         ) and to evaluate for venous hypertension. Doppler ultrasound examination is also the standard tool used to evaluate any affected superficial veins and confirm upper extremity phlebitis. (See
         <a class="medical medical_review" href="/z/d/html/131420.html" rel="external">
          "Clinical features, diagnosis, and classification of thoracic central venous obstruction", section on 'Vascular imaging'
         </a>
         .)
        </p>
        <p>
         Additional studies may include computed tomographic (CT) or magnetic resonance venography  (
         <a class="graphic graphic_diagnosticimage graphicRef120528" href="/z/d/graphic/120528.html" rel="external">
          image 11
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef120530" href="/z/d/graphic/120530.html" rel="external">
          image 12
         </a>
         ), or digital subtraction venography depending on the suspected etiology.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Vascular imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome", section on 'Approach to imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         CT pulmonary angiography is warranted in those with chest pain or dyspnea and to rule out pulmonary embolism.
        </p>
        <p class="headingAnchor" id="H3217687324">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H176084320">
         <span class="h2">
          Asymptomatic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asymptomatic nonthrombotic TCVO does not require specific treatment except in situations where improvement of venous outflow is necessary for a hemodialysis arteriovenous access candidate. Patients with central venous access devices who have a venous stenosis without thrombus but are otherwise asymptomatic can be observed.
        </p>
        <p>
         Whether patients with asymptomatic nonthrombotic TCVO (ie, thoracic/upper extremity deep vein thrombosis [DVT]) should be treated is more controversial and less well defined than treatment of symptomatic thrombosis. While asymptomatic thrombosis in the lower extremity is well recognized as a source of embolization, the rate of this or other complications with asymptomatic thoracic central vein thrombosis is not known [
         <a href="#rid100">
          100
         </a>
         ]. Consequently, the risk/benefit analysis of any potential treatment cannot be determined. However, there is no theoretical reason to believe that the risk of embolization is any different compared with symptomatic thoracic central vein thrombi, unless chronic in nature. In addition, asymptomatic upper extremity DVT can cause permanent obstruction in the subclavian vein and may result in loss of central venous access on the affected side. As an example of this last point, one series noted that 14 percent of patients undergoing a second or third catheter placement failed the procedure because of obstruction. Therefore, barring any contraindications, anticoagulation should be administered in accordance with the recommendations below. (See
         <a class="local">
          'Anticoagulation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1737589963">
         <span class="h2">
          Symptomatic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial treatment of symptomatic TCVO is aimed at relieving symptoms, which includes reducing pain from associated superficial vein thrombosis and phlebitis, controlling limb edema, minimizing the risk for embolization by providing systemic anticoagulation for those with thrombotic obstruction (ie, upper extremity DVT), and providing for continued intravenous access, if it is needed. However, while anticoagulation reduces propagation of thrombus, it does little to resolve acute clot. Depending on the duration and severity of symptoms, subsequent treatment is tailored to address underlying venous and other anatomic abnormalities through venous intervention or surgery. (See
         <a class="local">
          'Anticoagulation'
         </a>
         below and
         <a class="local">
          'Endovenous intervention'
         </a>
         below and
         <a class="local">
          'Etiology-specific considerations'
         </a>
         below.)
        </p>
        <p>
         Thoracic/upper extremity DVT secondary to intravenous catheters is generally managed more conservatively compared with primary, spontaneous upper extremity TCVO. The more aggressive approach used with spontaneous thrombosis is due to a higher incidence of postphlebitic sequelae. In a systematic review, the incidence of postthrombotic syndrome (PTS) ranged from 7 to 46 percent following upper extremity DVT in adults [
         <a href="#rid101">
          101
         </a>
         ]. Residual thrombosis and axillosubclavian vein thrombosis were associated with PTS, but catheter-associated upper extremity DVT was associated with reduced risk. (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis"
         </a>
         .)
        </p>
        <p>
         Superficial vein thrombosis and phlebitis may accompany thrombotic TCVO and may be more commonly associated with catheter-related TCVO, particularly the use of peripherally inserted central venous catheters (PICCs). Phlebitis and PICC-related thrombosis may occur in up to 28 percent of patients [
         <a href="#rid89">
          89,102
         </a>
         ]. There are limited data to guide management of upper extremity superficial vein thrombosis and phlebitis and much of the care is extrapolated from studies of the lower extremity, including limb elevation, nonsteroidal anti-inflammatory agents, compression therapy. The role of anticoagulation in the management of upper extremity superficial vein thrombosis and phlebitis not associated with DVT (ie, TCVO) is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Superficial vein thrombosis and phlebitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2475555223">
         <span class="h3">
          Thrombotic TCVO
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite a lack of direct evidence proving safety and efficacy of anticoagulation for thoracic/upper extremity DVT, anticoagulation for three months with adjunctive venous intervention in selected patients remains the cornerstone of therapy with a goal of relieving acute symptoms and preventing embolization  (
         <a class="graphic graphic_algorithm graphicRef139014" href="/z/d/graphic/139014.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid103">
          103-106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2747443896">
         <span class="h4">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with thrombotic TCVO (ie, thoracic/upper extremity DVT), we recommend anticoagulation as described for iliocaval/lower extremity DVT, provided there are no contraindications. This recommendation is consistent with guidelines from the American College of Chest Physicians and other international guidelines [
         <a href="#rid105">
          105,107-109
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at low risk of bleeding'
         </a>
         .)
        </p>
        <p>
         Pulmonary embolism is overall less common for patients with thrombosis involving the thoracic central veins/upper extremity veins, compared with lower extremity DVT [
         <a href="#rid110">
          110,111
         </a>
         ]. Nevertheless, venous thromboembolism is still a serious problem. Thus, therapy for TCVO/upper extremity DVT is directed toward preventing this complication. Anticoagulation is generally effective for preventing pulmonary embolism in patients with lower extremity DVT. By inference, anticoagulation should also be effective for preventing embolization from thrombosed thoracic/upper extremity veins, although treatment failures occur at both locations [
         <a href="#rid112">
          112
         </a>
         ]. However, no treatment scheme has been rigorously evaluated for its efficacy in preventing embolization from upper extremity sources. As a result, recommendations for the treatment of thoracic/upper extremity DVT are based largely upon indirect evidence from the experience with DVT of the lower extremities. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         .)
        </p>
        <p>
         The author's practice is to offer full anticoagulation therapy for three months, if not contraindicated, for patients who present acutely (&lt;14 days) or subacutely (ie, between 14 days and three months) from the onset of symptoms, but no anticoagulation for those who present chronically (ie, after three months). Chronic fibrotic obstruction of subclavian/axillary veins is associated with a delayed presentation. Patients with chronic symptoms related to TCVO are less likely to benefit from anticoagulation, and even after successful endovenous or surgical intervention, these patients have poorer outcomes [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
         The type and intensity of anticoagulation is like recommendations to prevent embolization of thrombi from the deep veins of the lower extremities. We suggest initial therapy with parenteral anticoagulants (low-molecular-weight heparin [LMWH],
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         ,
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         ) followed by LMWH or a vitamin K antagonist (eg,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ). Sufficient data are lacking to recommend the use of a direct oral anticoagulant (DOAC) for the management of the acute phase of thoracic/upper extremity DVT. However, observational and small controlled studies examining the utility of DOACs in upper extremity thrombosis are emerging [
         <a href="#rid114">
          114,115
         </a>
         ]. Therapeutic options for DVT are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         .)
        </p>
        <p>
         The optimal strategy for patients who have contraindications to systemic anticoagulation is unknown. Venous intervention may be performed but must be considered on a case-by-case basis. The use of superior vena cava (SVC) filters remains one of the most controversial issues among clinicians and there are no randomized studies to support routine use. Their use should be limited to those with contraindications to anticoagulation and documented pulmonary embolism. Because of the lower risk of clinically significant pulmonary embolism in upper extremity DVT, potential benefit must outweigh the significant risks of SVC filter placement, including filter embolization or filter thrombosis. In one review, 3 percent had major filter-related complications [
         <a href="#rid116">
          116
         </a>
         ]. These included SVC perforation in 6, cardiac tamponade in 4, aortic perforation in 2, SVC thrombosis in 2, and pneumothorax in 1.
        </p>
        <p class="headingAnchor" id="H2346352063">
         <span class="h4">
          Endovenous intervention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endovenous intervention has revolutionized the ability to address and treat TCVO. Endovenous intervention may help reduce the long-term sequelae of the thrombotic event (ie, postthrombotic syndrome). For those with severe manifestations of TCVO, such as SVC syndrome or phlegmasia cerulea dolens, endovenous intervention can be life- or limb-saving. Appropriate expertise and institutional resources must be available to provide this intervention. If such resources are not available, patients with severe symptoms should be considered for transfer, and for others, anticoagulation with interval follow-up vascular imaging is a reasonable alternative. (See
         <a class="medical medical_review" href="/z/d/html/120732.html" rel="external">
          "Endovenous intervention for thoracic central venous obstruction"
         </a>
         .)
        </p>
        <p>
         The goals of endovenous intervention in those with acute thrombotic (&lt;14 days) TCVO is to decrease the volume of thrombus using catheter-directed thrombolysis (CDT), if not contraindicated  (
         <a class="graphic graphic_table graphicRef95035" href="/z/d/graphic/95035.html" rel="external">
          table 4
         </a>
         ), and then to evaluate for any underlying intrinsic venous stenosis and, if present, perform angioplasty with or without stenting of the diseased vein segment depending on the likely etiology. However, for those with TCVO due to venous thoracic outlet syndrome (vTOS), venous stenting should be avoided prior to thoracic outlet decompression. Moreover, most patients with catheter-related thoracic/upper extremity DVT do
         <strong>
          not
         </strong>
         need catheter-directed thrombolytic therapy, although some authors have advocated its use. (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Early diagnosis is critical, and in the author's opinion, it is acceptable to perform CDT up to 14 days from the onset of symptoms. The effectiveness of endovenous intervention has been well reported. Many experts have shown a recanalization rate up to 80 percent with early CDT (≤14 days) [
         <a href="#rid117">
          117,118
         </a>
         ]. On the other hand, patency rate drops significantly to 29 percent after two weeks [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
         Because thrombolytic therapy aims to minimize long-term symptoms, the impact on the patient's quality of life should first be determined. Catheter-directed thrombolytic therapy may be reasonable for individuals with significant symptoms in the acute stages of thrombosis (symptoms less than 14 days) who have met all of the following criteria (see
         <a class="medical medical_review" href="/z/d/html/120732.html" rel="external">
          "Endovenous intervention for thoracic central venous obstruction"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have not adequately responded to systematic anticoagulation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have a low risk for bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have a good long-term prognosis relative to their underlying disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have a lifestyle that requires vigorous use of the affected arm
        </p>
        <p>
        </p>
        <p>
         Patients who do not meet these criteria (eg, a patient with limited life expectancy from their coexistent medical problems who does not require extensive use of their arm) are likely to do just as well with conservative therapy, consisting of symptomatic care and anticoagulation.
        </p>
        <p class="headingAnchor" id="H1229731040">
         <span class="h3">
          Nonthrombotic TCVO
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with nonthrombotic obstruction and moderate-to-severe symptoms such as swelling and pain, treatment is targeted toward reducing the severity of the stenotic venous lesion using angioplasty with or without stenting  (
         <a class="graphic graphic_diagnosticimage graphicRef120532" href="/z/d/graphic/120532.html" rel="external">
          image 13
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef120533" href="/z/d/graphic/120533.html" rel="external">
          image 14
         </a>
         ) depending on the likely etiology. (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Thrombolytic therapy'
         </a>
         .)
        </p>
        <p>
         For those with chronic onset TCVO, or those with incidental thrombus, the treatment approach is according to the presenting symptoms. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No specific treatment is recommended for patients without symptoms, even if thrombus is found incidentally.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A young, healthy patient with significant symptoms may benefit from an aggressive approach (ie, thoracic outlet decompression and venous reconstruction) whereas a frail, older adult will not fit for such approach.
        </p>
        <p>
        </p>
        <p>
         It is important to recognize external compression; attempts to dilate the vein with an angioplasty balloon will have no effect. Some have suggested stenting in cases with significant symptoms; however, placement of a stent may be difficult owing to the large size of the vein, and in those with costoclavicular compression, stenting is ill advised, as it is ineffective, may result in stent fracture, and complicates subsequent surgical management [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3243510679">
         <span class="h2">
          Etiology-specific considerations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Catheter-related
         </strong>
         – Indwelling catheters or wires contribute to most cases of TCVO. Anticoagulation and angioplasty with or without stenting are the main components of the therapy. Whether to remove an indwelling device depends upon the ongoing need for the device, and whether it is functioning or occluded. (See
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Catheter management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1906.html" rel="external">
          "Malfunction of chronic hemodialysis catheters", section on 'Catheter-related central venous thrombosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Managing hemodialysis arteriovenous access
         </strong>
         – Patients on hemodialysis with hemodynamically and clinically significant central venous stenosis benefit from venous intervention to restore central venous patency. (See
         <a class="medical medical_review" href="/z/d/html/1913.html" rel="external">
          "Central vein obstruction associated with upper extremity hemodialysis access"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These patients should also be carefully evaluated for possible vTOS. Affected patients may benefit from periclavicular first rib resection, scalenectomy, and venolysis [
         <a href="#rid120">
          120
         </a>
         ]. Interestingly, patients with chronic vTOS benefit as much from decompression as those with acute vTOS [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thoracic outlet decompression
         </strong>
         – Thrombotic vTOS is often managed with systemic anticoagulation followed by CDT, if not contraindicated. First rib resection may be appropriate in selected patients, taking into consideration the severity of symptoms, adequacy of collateral circulation, and intended activity level. Many respected authorities have recommended infraclavicular first rib resection followed by concomitant postoperative venous balloon angioplasty in same admission with excellent midterm outcomes [
         <a href="#rid122">
          122,123
         </a>
         ]. Anticoagulation alone is not recommended secondary to poor outcomes, and thoracic outlet decompression surgery should follow within the same admission or within six to eight weeks [
         <a href="#rid117">
          117
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8211.html" rel="external">
          "Primary (spontaneous) upper extremity deep vein thrombosis", section on 'Thoracic outlet decompression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of malignancy
         </strong>
         – Treatment of TCVO will depend on the clinical presentation and the severity of TCVO in addition to timing of other oncological treatment as radiation of chemotherapy. Even with thrombotic TCVO secondary to indwelling catheter, we prefer to start full anticoagulation and to leave catheters in place until completion of therapy, and then it might be removed. (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Traumatic injury
         </strong>
         – For patients who present with acute venous obstruction related to iatrogenic or traumatic injury, venous repair may be warranted. (See
         <a class="medical medical_review" href="/z/d/html/15227.html" rel="external">
          "Overview of blunt and penetrating thoracic vascular injury in adults", section on 'Great vessel injury'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H139389561">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113663.html" rel="external">
          "Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117743.html" rel="external">
          "Society guideline links: Venous access"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118466.html" rel="external">
          "Society guideline links: Chronic venous disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4255440763">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thoracic central venous obstruction
         </strong>
         – Thoracic central venous obstruction (TCVO) encompasses a spectrum of conditions affecting the veins in the chest. The most common cause of TCVO is vein injury related to placement of intravascular devices into the thoracic central venous system (TCVS), primarily indwelling central venous catheters and pacemaker leads. Other etiologies include conditions that injure or compress the vein (eg, thoracic outlet syndromes, malignant obstruction, aneurysmal disease) and conditions that increase the risk for venous thrombosis. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Etiologies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anatomy and collateral venous flow
         </strong>
         – The TCVS includes the intrathoracic portion of the internal jugular veins, the subclavian veins  (
         <a class="graphic graphic_figure graphicRef82344" href="/z/d/graphic/82344.html" rel="external">
          figure 8
         </a>
         ), and the brachiocephalic veins bilaterally, which join to form the superior vena cava (SVC). When TCVO develops, drainage of venous blood relies mainly on the azygos and hemiazygos veins to return blood to the heart  (
         <a class="graphic graphic_figure graphicRef81142" href="/z/d/graphic/81142.html" rel="external">
          figure 3
         </a>
         ). Occlusion of SVC impairs azygous flow and leads to the most severe type of TCVO. (See
         <a class="local">
          'Central venous anatomy'
         </a>
         above and
         <a class="local">
          'Collateral venous circulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
         – TCVO is classified based on the presence of an inciting etiology (ie, secondary) or not (ie, primary). TCVO can be also classified anatomically based on the location of affected veins  (
         <a class="graphic graphic_figure graphicRef117576" href="/z/d/graphic/117576.html" rel="external">
          figure 6
         </a>
         ). TCVO is either thrombotic or nonthrombotic based upon the presence or absence of thrombus, respectively. (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentations
         </strong>
         – The clinical presentation of TCVO varies depending on the time course of symptoms (acute, intermittent, chronic), severity of obstruction (partial, complete), location of obstruction, and the extent of any venous compensation (ie, collateral flow). Symptoms range from mild to severe and include predominantly pain and edema (extremity, facial), but other symptoms can occur. (See
         <a class="local">
          'Clinical presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – A diagnosis of TCVO may be suspected based upon history and physical exam but requires demonstration of the stenotic lesion or thrombus affecting the thoracic central veins on venous imaging studies. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment of symptomatic TCVO is aimed at relieving symptoms, which includes reducing pain from phlebitis and preventing pulmonary embolism for those with thrombotic obstruction. Subsequent treatment of symptomatic TCVO is tailored to address underlying venous and other anatomic abnormalities using a variety of endovascular and surgical options. Asymptomatic TCVO does not require specific treatment except when needed to improve venous outflow for hemodialysis arteriovenous access. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anticoagulation
         </strong>
         – For patients with thrombotic TCVO (ie, thoracic/upper extremity deep vein thrombosis), we suggest anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For uncomplicated cases, three months of anticoagulation therapy should be sufficient. A longer duration of anticoagulation may be warranted when a central venous catheter is left in place, particularly for patients with malignancy. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8195.html" rel="external">
          "Catheter-related upper extremity venous thrombosis in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Catheter-directed thrombolytic therapy
         </strong>
         – For patients with thrombotic TCVO with severe symptoms of duration &lt;14 days, we suggest catheter-directed thrombolytic therapy for patients who meet the following criteria (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (see
         <a class="local">
          'Endovenous intervention'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Does not have catheter-related venous thrombosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Has not adequately responded to systematic anticoagulation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Has a low risk for bleeding
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Has a good long-term prognosis relative to their underlying disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Has a lifestyle that requires vigorous use of the affected arm
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kruger SJ. Breast cancer presenting as subclavian/axillary deep vein thrombosis and upper limb lymphoedema. Ann R Coll Surg Engl 2012; 94:e55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolmatch BL, Gurley JC, Baskin KM, et al. Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI). J Vasc Interv Radiol 2018; 29:454.
          </a>
         </li>
         <li class="breakAll">
          Dauber W. Veins. In: Pocket Atlas of Human Anatomy, 5, Thieme, Stuttgart 2007. p.273.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baskin KM, Jimenez RM, Cahill AM, et al. Cavoatrial junction and central venous anatomy: implications for central venous access tip position. J Vasc Interv Radiol 2008; 19:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marini TJ, Chughtai K, Nuffer Z, et al. Blood finds a way: pictorial review of thoracic collateral vessels. Insights Imaging 2019; 10:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur S, Paik E, Rezaei A, Vu DN. Where there is blood, there is a way: unusual collateral vessels in superior and inferior vena cava obstruction. Radiographics 2010; 30:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Illig KA, Donahue D, Duncan A, et al. Reporting standards of the Society for Vascular Surgery for thoracic outlet syndrome. J Vasc Surg 2016; 64:e23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wooster M, Fernandez B, Summers KL, Illig KA. Surgical and endovascular central venous reconstruction combined with thoracic outlet decompression in highly symptomatic patients. J Vasc Surg Venous Lymphat Disord 2019; 7:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards JB, Brooks JD, Wooster MD, et al. Outcomes of venous bypass combined with thoracic outlet decompression for treatment of upper extremity central venous occlusion. J Vasc Surg Venous Lymphat Disord 2019; 7:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magee C, Jones C, McIntosh S, Harkin DW. Upper limb deep vein thrombosis due to Langer's axillary arch. J Vasc Surg 2012; 55:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lum YW, Brooke BS, Likes K, et al. Impact of anterior scalene lidocaine blocks on predicting surgical success in older patients with neurogenic thoracic outlet syndrome. J Vasc Surg 2012; 55:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melby SJ, Vedantham S, Narra VR, et al. Comprehensive surgical management of the competitive athlete with effort thrombosis of the subclavian vein (Paget-Schroetter syndrome). J Vasc Surg 2008; 47:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glass C, Dugan M, Gillespie D, et al. Costoclavicular venous decompression in patients with threatened arteriovenous hemodialysis access. Ann Vasc Surg 2011; 25:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Illig KA, Gabbard W, Calero A, et al. Aggressive Costoclavicular Junction Decompression in Patients with Threatened AV Access. Ann Vasc Surg 2015; 29:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Itkin M, Kraus MJ, Trerotola SO. Extrinsic compression of the left innominate vein in hemodialysis patients. J Vasc Interv Radiol 2004; 15:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin J, Qi Z, Chen Y, Chen Y. A case report of membranous occlusion of the subclavian vein: a rare cause of McCleery syndrome. Ann Transl Med 2021; 9:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Likes K, Rochlin DH, Call D, Freischlag JA. McCleery syndrome: etiology and outcome. Vasc Endovascular Surg 2014; 48:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warden GD, Wilmore DW, Pruitt BA Jr. Central venous thrombosis: a hazard of medical progress. J Trauma 1973; 13:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Criado E, Marston WA, Jaques PF, et al. Proximal venous outflow obstruction in patients with upper extremity arteriovenous dialysis access. Ann Vasc Surg 1994; 8:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mickley V. Central vein obstruction in vascular access. Eur J Vasc Endovasc Surg 2006; 32:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tapaneeyakorn J, Inman T, Panpikul T, et al. Vascular access stenosis and central vein obstruction interventions: five years of experience in Ramathibodi Hospital. J Med Assoc Thai 2012; 95:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safety Committee of Japanese Society of Anesthesiologists. Practical guide for safe central venous catheterization and management 2017. J Anesth 2020; 34:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lumsden AB, MacDonald MJ, Isiklar H, et al. Central venous stenosis in the hemodialysis patient: incidence and efficacy of endovascular treatment. Cardiovasc Surg 1997; 5:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witte KK, Kelly SJ, Parker JD, Nanthakumar K. Deployment of left ventricular lead from the ipsilateral side of central vein obstruction. J Interv Card Electrophysiol 2005; 13:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang CL, Tarng DC, Yang WC, Huang TP. An occult cause of arteriovenous access failure: central vein stenosis from permanent pacemaker wire. Report of three cases and review of the literature. Am J Nephrol 2001; 21:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone WJ, Wall MN, Powers TA. Massive upper extremity edema with arteriovenous fistula for hemodialysis. A complication of previous pacemaker insertion. Nephron 1982; 31:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forauer AR, Theoharis C. Histologic changes in the human vein wall adjacent to indwelling central venous catheters. J Vasc Interv Radiol 2003; 14:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponz E, Campistol Plana JM, Almirall J, et al. Mechanism of hemodialysis-associated subclavian vein stenosis. Nephron 1990; 56:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwab SJ, Quarles LD, Middleton JP, et al. Hemodialysis-associated subclavian vein stenosis. Kidney Int 1988; 33:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dethlefsen SM, Shepro D, D'Amore PA. Comparison of the effects of mechanical stimulation on venous and arterial smooth muscle cells in vitro. J Vasc Res 1996; 33:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salgado OJ, Urdaneta B, Colmenares B, et al. Right versus left internal jugular vein catheterization for hemodialysis: complications and impact on ipsilateral access creation. Artif Organs 2004; 28:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin BS, Kong CW, Tarng DC, et al. Anatomical variation of the internal jugular vein and its impact on temporary haemodialysis vascular access: an ultrasonographic survey in uraemic patients. Nephrol Dial Transplant 1998; 13:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney Int 1999; 56:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wivell W, Bettmann MA, Baxter B, et al. Outcomes and performance of the Tesio twin catheter system placed for hemodialysis access. Radiology 2001; 221:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saseedharan S, Bhargava S. Upper extremity deep vein thrombosis. Int J Crit Illn Inj Sci 2012; 2:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest 2005; 128:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yukisawa S, Fujiwara Y, Yamamoto Y, et al. Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients. Br J Radiol 2010; 83:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabatabaie O, Kasumova GG, Kent TS, et al. Upper extremity deep venous thrombosis after port insertion: What are the risk factors? Surgery 2017; 162:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fallouh N, McGuirk HM, Flanders SA, Chopra V. Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review. Am J Med 2015; 128:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Incidence of central vein stenosis and occlusion following upper extremity PICC and port placement. Cardiovasc Intervent Radiol 2003; 26:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin YX, Gao W, Li XY, et al. Randomized multicenter study on long-term complications of peripherally inserted central catheters positioned by electrocardiographic technique. Phlebology 2020; 35:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen H, Zhang X, Wang H, Hu X. Complications of upper extremity versus lower extremity placed peripherally inserted central catheters in neonatal intensive care units: A meta-analysis. Intensive Crit Care Nurs 2020; 56:102753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krein SL, Saint S, Trautner BW, et al. Patient-reported complications related to peripherally inserted central catheters: a multicentre prospective cohort study. BMJ Qual Saf 2019; 28:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertoglio S, Faccini B, Lalli L, et al. Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures. J Surg Oncol 2016; 113:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupont C, Gouya H, Panzo R, et al. Complications of peripherally inserted central catheters in adults with cystic fibrosis or bronchiectasis. J Vasc Access 2015; 16:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nifong TP, McDevitt TJ. The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters. Chest 2011; 140:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson TJ, Brown DL, Meurer WJ, et al. Risk factors associated with peripherally inserted central venous catheter-related large vein thrombosis in neurological intensive care patients. Intensive Care Med 2012; 38:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular Complications of Central Venous Catheterization by Insertion Site. N Engl J Med 2015; 373:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen AW, Megargell JL, Brown DB, et al. Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad TF, Vesely TM. Venous access for patients with chronic kidney disease. J Vasc Interv Radiol 2004; 15:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twardowski ZJ, Seger RM. Dimensions of central venous structures in humans measured in vivo using magnetic resonance imaging: implications for central-vein catheter dimensions. Int J Artif Organs 2002; 25:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salik E, Daftary A, Tal MG. Three-dimensional anatomy of the left central veins: implications for dialysis catheter placement. J Vasc Interv Radiol 2007; 18:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobato EB, Sulek CA, Moody RL, Morey TE. Cross-sectional area of the right and left internal jugular veins. J Cardiothorac Vasc Anesth 1999; 13:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ince ME, Ozkan G, Ors N, et al. Complications and pitfalls of central venous port catheters: experience with 782 patients with cancer. Ir J Med Sci 2020; 189:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lescinskas EH, Trautner BW, Saint S, et al. Use of and patient-reported complications related to midline catheters and peripherally inserted central catheters. Infect Control Hosp Epidemiol 2020; 41:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mushtaq A, Navalkele B, Kaur M, et al. Comparison of complications in midlines versus central venous catheters: Are midlines safer than central venous lines? Am J Infect Control 2018; 46:788.
          </a>
         </li>
         <li class="breakAll">
          Skillman JJ. Superficial phlebitis: Inflammatory, infectious associated with deep vein thrombosis. In: Decision Making in Vascular Surgery, Cronenwett JL, Rutherford RB (Eds), WB Saunders, Philadelphia 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cape AV, Mogensen KM, Robinson MK, Carusi DA. Peripherally inserted central catheter (PICC) complications during pregnancy. JPEN J Parenter Enteral Nutr 2014; 38:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacques L, Foeller M, Farez R, et al. Safety of peripherally inserted central catheters during pregnancy: a retrospective study. J Matern Fetal Neonatal Med 2018; 31:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli I, Battaglioli T, Bucciarelli P, et al. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vayá A, Mira Y, Mateo J, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Héron E, Lozinguez O, Alhenc-Gelas M, et al. Hypercoagulable states in primary upper-extremity deep vein thrombosis. Arch Intern Med 2000; 160:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao AK, Chitkara U, Milki AA. Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report. Hum Reprod 2005; 20:3307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chopra V, Kaatz S, Conlon A, et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis. J Thromb Haemost 2017; 15:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ejima K, Shoda M, Manaka T, et al. Left brachiocephalic vein occlusion in a patient with an aortic arch aneurysm: Rare cause of obstraction for a pacemaker implantation. J Cardiol Cases 2014; 9:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haq AA, Restrepo CS, Lamus D, et al. Thoracic venous injuries: an imaging and management overview. Emerg Radiol 2016; 23:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holly BP, Steenburg SD. Multidetector CT of blunt traumatic venous injuries in the chest, abdomen, and pelvis. Radiographics 2011; 31:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PEET RM, HENRIKSEN JD, ANDERSON TP, MARTIN GM. Thoracic-outlet syndrome: evaluation of a therapeutic exercise program. Proc Staff Meet Mayo Clin 1956; 31:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCLEERY RS, KESTERSON JE, KIRTLEY JA, LOVE RB. Subclavius and anterior scalene muscle compression as a cause of intermittent obstruction of the subclavian vein. Ann Surg 1951; 133:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parienty R, Michel JR. [Paget-Von Schrötter syndrome: so-called "effort" phlebitis of the upper extremity]. Ann Radiol (Paris) 1965; 8:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aziz S, Straehley CJ, Whelan TJ Jr. Effort-related axillosubclavian vein thrombosis. A new theory of pathogenesis and a plea for direct surgical intervention. Am J Surg 1986; 152:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jusufovic M, Sandset EC, Popperud TH, et al. An unusual case of the syndrome of cervical rib with subclavian artery thrombosis and cerebellar and cerebral infarctions. BMC Neurol 2012; 12:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Autio E, Lindholm S, Lindholm R. Effort thrombosis of the subclavian vein. Repot of a case of the Paget-Schrötter syndrome. Ann Chir Gynaecol Fenn 1968; 57:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindblad B, Tengborn L, Bergqvist D. Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg 1988; 2:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry MA, Hajarnavis J. Paget-von Schrötter syndrome: primary subclavian-axillary vein thrombosis in sport activities. Clin J Sport Med 2003; 13:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claes T, Debeer P, Bellemans J, Claes T. Deep venous thrombosis of the axillary and subclavian vein after osteosynthesis of a midshaft clavicular fracture: a case report. Am J Sports Med 2010; 38:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim EV, Day LJ. Subclavian vein thrombosis following fracture of the clavicle. A case report. Orthopedics 1987; 10:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flinterman LE, Van Der Meer FJ, Rosendaal FR, Doggen CJ. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 2008; 6:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warkentin TE, Cook DJ. Current perspective of venous thrombosis in the upper extremity: a rebuttal. J Thromb Haemost 2009; 7:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leebeek FW, Stadhouders NA, van Stein D, et al. Hypercoagulability states in upper-extremity deep venous thrombosis. Am J Hematol 2001; 67:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998; 58:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. Br J Haematol 2010; 149:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhakta A, Tafen M, Ahmed M, et al. Risk of catheter-associated deep venous thrombosis in inflammatory bowel disease. Dis Colon Rectum 2014; 57:1379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21:3665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamontagne F, McIntyre L, Dodek P, et al. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study. JAMA Intern Med 2014; 174:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decousus H, Bourmaud A, Fournel P, et al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood 2018; 132:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders RJ, Hammond SL. Subclavian vein obstruction without thrombosis. J Vasc Surg 2005; 41:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thakur S, Comerota AJ. Bilateral nonthrombotic subclavian vein obstruction causing upper extremity venous claudication. J Vasc Surg 2010; 52:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Illig KA, Doyle AJ. A comprehensive review of Paget-Schroetter syndrome. J Vasc Surg 2010; 51:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillard J, Pérez-Cousin M, Hachulla E, et al. Diagnosing thoracic outlet syndrome: contribution of provocative tests, ultrasonography, electrophysiology, and helical computed tomography in 48 patients. Joint Bone Spine 2001; 68:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maslovsky I, Gefel D. Paget-von Schrötter syndrome. Am J Med 2006; 119:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders RJ, Haug C. Subclavian vein obstruction and thoracic outlet syndrome: a review of etiology and management. Ann Vasc Surg 1990; 4:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pistorius MA, Planchon B. Incidence of thoracic outlet syndrome on the epidemiology and clinical presentation of apparently primary Raynaud's phenomenon. A prospective study in 570 patients. Int Angiol 1995; 14:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dammers R, de Haan MW, Planken NR, et al. Central vein obstruction in hemodialysis patients: results of radiological and surgical intervention. Eur J Vasc Endovasc Surg 2003; 26:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006; 117:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aw A, Carrier M, Koczerginski J, et al. Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. Thromb Res 2012; 130:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debourdeau P, Kassab Chahmi D, Le Gal G, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol 2009; 20:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008; 112:4818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajasekhar A, Streiff MB. How I treat central venous access device-related upper extremity deep vein thrombosis. Blood 2017; 129:2727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valeriani E, Di Nisio M, Porceddu E, et al. Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis. J Thromb Haemost 2022; 20:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ageno W, Haas S, Weitz JI, et al. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thromb Haemost 2019; 119:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study. Thromb Haemost 1994; 72:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina JE, Hunter DW, Dietz CA. Protocols for Paget-Schroetter syndrome and late treatment of chronic subclavian vein obstruction. Ann Thorac Surg 2009; 87:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porfidia A, Agostini F, Giarretta I, et al. Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. J Thromb Thrombolysis 2020; 50:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montiel FS, Ghazvinian R, Gottsäter A, Elf J. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J 2017; 15:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens CA, Bui JT, Knuttinen MG, et al. Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 2010; 21:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doyle A, Wolford HY, Davies MG, et al. Management of effort thrombosis of the subclavian vein: today's treatment. Ann Vasc Surg 2007; 21:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelman MA, Stone DH, Riles TS, et al. A multidisciplinary approach to the treatment of Paget-Schroetter syndrome. Ann Vasc Surg 1997; 11:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome treated with thrombolytics and immediate surgery. J Vasc Surg 2007; 45:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim S, Alarhayem AQ, Rowse JW, et al. Thoracic outlet decompression for subclavian venous stenosis after ipsilateral hemodialysis access creation. J Vasc Surg Venous Lymphat Disord 2021; 9:1473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman SC, Singh MJ, Lowenkamp MN, et al. Postoperative outcomes in thoracic outlet decompression for acute versus chronic venous thoracic outlet syndrome. J Vasc Surg Venous Lymphat Disord 2021; 9:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madden N, Calligaro KD, Dougherty MJ, et al. Evolving strategies for the management of venous thoracic outlet syndrome. J Vasc Surg Venous Lymphat Disord 2019; 7:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samoila G, Twine CP, Williams IM. The infraclavicular approach for Paget-Schroetter syndrome. Ann R Coll Surg Engl 2018; 100:83.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 17036 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22391349" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Breast cancer presenting as subclavian/axillary deep vein thrombosis and upper limb lymphoedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29503236" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29503236" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Society of Interventional Radiology Reporting Standards for Thoracic Central Vein Obstruction: Endorsed by the American Society of Diagnostic and Interventional Nephrology (ASDIN), British Society of Interventional Radiology (BSIR), Canadian Interventional Radiology Association (CIRA), Heart Rhythm Society (HRS), Indian Society of Vascular and Interventional Radiology (ISVIR), Vascular Access Society of the Americas (VASA), and Vascular Access Society of Britain and Ireland (VASBI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18295694" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cavoatrial junction and central venous anatomy: implications for central venous access tip position.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31197577" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Blood finds a way: pictorial review of thoracic collateral vessels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083586" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Where there is blood, there is a way: unusual collateral vessels in superior and inferior vena cava obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27565607" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Reporting standards of the Society for Vascular Surgery for thoracic outlet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30442583" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Surgical and endovascular central venous reconstruction combined with thoracic outlet decompression in highly symptomatic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31176658" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Outcomes of venous bypass combined with thoracic outlet decompression for treatment of upper extremity central venous occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21924577" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Upper limb deep vein thrombosis due to Langer's axillary arch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22459745" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Impact of anterior scalene lidocaine blocks on predicting surgical success in older patients with neurogenic thoracic outlet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280096" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Comprehensive surgical management of the competitive athlete with effort thrombosis of the subclavian vein (Paget-Schroetter syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514107" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Costoclavicular venous decompression in patients with threatened arteriovenous hemodialysis access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724289" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Aggressive Costoclavicular Junction Decompression in Patients with Threatened AV Access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14709688" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Extrinsic compression of the left innominate vein in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33553371" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A case report of membranous occlusion of the subclavian vein: a rare cause of McCleery syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24334914" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : McCleery syndrome: etiology and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4715030" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Central venous thrombosis: a hazard of medical progress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7865390" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Proximal venous outflow obstruction in patients with upper extremity arteriovenous dialysis access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16765068" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Central vein obstruction in vascular access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23140040" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Vascular access stenosis and central vein obstruction interventions: five years of experience in Ramathibodi Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31786676" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Practical guide for safe central venous catheterization and management 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9464608" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Central venous stenosis in the hemodialysis patient: incidence and efficacy of endovascular treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15976978" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Deployment of left ventricular lead from the ipsilateral side of central vein obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11684804" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : An occult cause of arteriovenous access failure: central vein stenosis from permanent pacemaker wire. Report of three cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7121661" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Massive upper extremity edema with arteriovenous fistula for hemodialysis. A complication of previous pacemaker insertion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14514808" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Histologic changes in the human vein wall adjacent to indwelling central venous catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2243586" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mechanism of hemodialysis-associated subclavian vein stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2969991" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hemodialysis-associated subclavian vein stenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8862146" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Comparison of the effects of mechanical stimulation on venous and arterial smooth muscle cells in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15270954" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Right versus left internal jugular vein catheterization for hemodialysis: complications and impact on ipsilateral access creation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9481729" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Anatomical variation of the internal jugular vein and its impact on temporary haemodialysis vascular access: an ultrasonographic survey in uraemic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10411674" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The hemodialysis catheter conundrum: hate living with them, but can't live without them.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719665" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Outcomes and performance of the Tesio twin catheter system placed for hemodialysis access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22624098" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Upper extremity deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16100130" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20223904" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Upper-extremity deep vein thrombosis related to central venous port systems implanted in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28535970" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Upper extremity deep venous thrombosis after port insertion: What are the risk factors?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25697969" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12616419" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incidence of central vein stenosis and occlusion following upper extremity PICC and port placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32375605" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Randomized multicenter study on long-term complications of peripherally inserted central catheters positioned by electrocardiographic technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31445794" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Complications of upper extremity versus lower extremity placed peripherally inserted central catheters in neonatal intensive care units: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30683751" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Patient-reported complications related to peripherally inserted central catheters: a multicentre prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27020965" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25656251" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Complications of peripherally inserted central catheters in adults with cystic fibrosis or bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21040443" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21349931" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22113818" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Risk factors associated with peripherally inserted central venous catheter-related large vein thrombosis in neurological intensive care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26398070" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intravascular Complications of Central Venous Catheterization by Insertion Site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099241" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Venous thrombosis associated with the placement of peripherally inserted central catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15466788" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Venous access for patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11905513" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Dimensions of central venous structures in humans measured in vivo using magnetic resonance imaging: implications for central-vein catheter dimensions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377181" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Three-dimensional anatomy of the left central veins: implications for dialysis catheter placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10230944" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cross-sectional area of the right and left internal jugular veins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32193794" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Complications and pitfalls of central venous port catheters: experience with 782 patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32127066" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Use of and patient-reported complications related to midline catheters and peripherally inserted central catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29525366" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Comparison of complications in midlines versus central venous catheters: Are midlines safer than central venous lines?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29525366" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Comparison of complications in midlines versus central venous catheters: Are midlines safer than central venous lines?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715775" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Peripherally inserted central catheter (PICC) complications during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28413891" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Safety of peripherally inserted central catheters during pregnancy: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15262837" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12624627" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10668841" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Hypercoagulable states in primary upper-extremity deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10917745" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16085662" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28796444" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30546779" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Left brachiocephalic vein occlusion in a patient with an aortic arch aneurysm: Rare cause of obstraction for a pacemaker implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26965007" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Thoracic venous injuries: an imaging and management overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21918052" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Multidetector CT of blunt traumatic venous injuries in the chest, abdomen, and pelvis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13323047" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Thoracic-outlet syndrome: evaluation of a therapeutic exercise program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14830129" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Subclavius and anterior scalene muscle compression as a cause of intermittent obstruction of the subclavian vein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5834219" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : [Paget-Von Schrötter syndrome: so-called "effort" phlebitis of the upper extremity].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3728818" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effort-related axillosubclavian vein thrombosis. A new theory of pathogenesis and a plea for direct surgical intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22741548" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : An unusual case of the syndrome of cervical rib with subclavian artery thrombosis and cerebellar and cerebral infarctions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5685027" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effort thrombosis of the subclavian vein. Repot of a case of the Paget-Schrötter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3410064" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12855931" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Paget-von Schrötter syndrome: primary subclavian-axillary vein thrombosis in sport activities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20348286" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Deep venous thrombosis of the axillary and subclavian vein after osteosynthesis of a midshaft clavicular fracture: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3562354" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Subclavian vein thrombosis following fracture of the clavicle. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18485082" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Current perspective of venous thrombosis in the upper extremity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17988232" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19130658" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Current perspective of venous thrombosis in the upper extremity: a rebuttal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100159" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Factor V Leiden in central venous catheter-associated thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279652" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Hypercoagulability states in upper-extremity deep venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625586" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Factor V Leiden mutation does not account for central venous catheter-related thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096009" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25380003" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Risk of catheter-associated deep venous thrombosis in inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506031" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14512399" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Venous thromboembolism associated with long-term use of central venous catheters in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24638843" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29980524" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15768011" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Subclavian vein obstruction without thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20434295" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Bilateral nonthrombotic subclavian vein obstruction causing upper extremity venous claudication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20304578" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A comprehensive review of Paget-Schroetter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11707008" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Diagnosing thoracic outlet syndrome: contribution of provocative tests, ultrasonography, electrophysiology, and helical computed tomography in 48 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16564790" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Paget-von Schrötter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2141997" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Subclavian vein obstruction and thoracic outlet syndrome: a review of etiology and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7658106" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Incidence of thoracic outlet syndrome on the epidemiology and clinical presentation of apparently primary Raynaud's phenomenon. A prospective study in 570 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14509897" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Central vein obstruction in hemodialysis patients: results of radiological and surgical intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8996041" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16002126" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22444157" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19525362" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805965" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : How I treat rare venous thromboses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26867832" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28373261" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : How I treat central venous access device-related upper extremity deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34352278" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315268" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23217208" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34846783" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31183844" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7878630" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Pulmonary embolism in patients with upper extremity DVT associated to venous central lines--a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19161749" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Protocols for Paget-Schroetter syndrome and late treatment of chronic subclavian vein obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32008208" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29026346" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20434365" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17923385" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Management of effort thrombosis of the subclavian vein: today's treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9181769" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : A multidisciplinary approach to the treatment of Paget-Schroetter syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264012" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Paget-Schroetter syndrome treated with thrombolytics and immediate surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33676044" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Thoracic outlet decompression for subclavian venous stenosis after ipsilateral hemodialysis access creation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32464288" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Postoperative outcomes in thoracic outlet decompression for acute versus chronic venous thoracic outlet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31471278" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Evolving strategies for the management of venous thoracic outlet syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29388461" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : The infraclavicular approach for Paget-Schroetter syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
